Cancer immunotherapeutic potential of NKTT320, a novel human invariant natural killer T-cell activating monoclonal antibody

被引：0
|
作者：
Das, Rupali [1 ]
Scheuplein, Felix [2 ]
Guan, Peng [1 ]
Schaub, Robert [2 ]
Nichols, Kim E. [3 ]
机构：
[1] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[2] NKT Therapeut, Waltham, MD USA
[3] St Jude Childrens Res Hosp, Memphis, TN 38105 USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-4294
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4294
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Cancer Immunotherapeutic Potential of NKTT320, a Novel, Invariant, Natural Killer T Cell-Activating, Humanized Monoclonal Antibody
    Patel, Nishant P.
    Guan, Peng
    Bahal, Devika
    Hashem, Tanwir
    Scheuplein, Felix
    Schaub, Robert
    Nichols, Kim E.
    Das, Rupali
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (12) : 1 - 17
  • [2] NKTT320, a novel monoclonal antibody activates the immuno-stimulatory functions of human invariant natural killer T cells
    Das, Rupali
    Scheuplein, Felix
    Patel, Nishant P.
    Guan, Peng
    Schaub, Robert G.
    Nichols, Kim E.
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [3] Immunomodulatory potential of in vivo natural killer T (NKT) activation by NKTT320 in Mauritian-origin cynomolgus macaques
    Bond, Nell G.
    Fahlberg, Marissa D.
    Yu, Shan
    Rout, Namita
    Tran, Dollnovan
    Fitzpatrick-Schmidt, Taylor
    Sprehe, Lesli M.
    Scheef, Elizabeth A.
    Mudd, Joseph C.
    Schaub, Robert
    Kaur, Amitinder
    [J]. ISCIENCE, 2022, 25 (03)
  • [4] Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11
    Montoya, Carlos J.
    Pollard, David
    Martinson, Jeffrey
    Kumari, Kumud
    Wasserfall, Clive
    Mulder, Candice B.
    Rugeles, Maria T.
    Atkinson, Mark A.
    Landay, Alan L.
    Wilson, S. Brian
    [J]. IMMUNOLOGY, 2007, 122 (01) : 1 - 14
  • [5] Invariant natural killer T-cell neutralization is a possible novel therapy for human eosinophilic esophagitis
    Rayapudi, Madhavi
    Rajavelu, Priya
    Zhu, Xiang
    Kaul, Ajay
    Niranjan, Rituraj
    Dynda, Scott
    Mishra, Akanksha
    Mattner, Jochen
    Zaidi, Asifa
    Dutt, Parmesh
    Mishra, Anil
    [J]. CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2014, 3
  • [6] Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer
    Peipp, Matthias
    Klausz, Katja
    Boje, Ammelie Svea
    Zeller, Tobias
    Zielonka, Stefan
    Kellner, Christian
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2022, 209 (01): : 22 - 32
  • [7] In vivo NKTT320-induced activation of invariant Natural Killer T-cells (iNKTs) and potential applications for use in AIDS pathogenesis modulation
    Bond, Nell G.
    Yu, Shan
    Rout, Namita
    Tran, Dollnovan
    Szeltner, Dawn
    Schaub, Robert
    Kaur, Amitinder
    [J]. JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
  • [8] NOVEL INVARIANT NATURAL KILLER T CELL-BASED CANCER IMMUNOTHERAPEUTICS
    Ferry, Gabrielle M.
    Altman, Jennie B.
    Benavides, Adriana D.
    Bassiri, Hamid
    [J]. JOURNAL OF CLINICAL IMMUNOLOGY, 2016, 36 (03) : 305 - 305
  • [9] NATURAL-KILLER (NK) CELL ACTIVATING FACTOR PRODUCED BY A HUMAN T-CELL HYBRIDOMA
    KOBAYASHI, Y
    YOSHIMATSU, K
    OSAWA, T
    [J]. MICROBIOLOGY AND IMMUNOLOGY, 1991, 35 (11) : 981 - 993
  • [10] NKTT320 mab-induced Natural Killer T lymphocyte activation promotes slower depletion of CCR5+CD4+T lymphocytes in acute SIV infection
    Zenere, Giorgio
    Bond, Nell
    Yu, Shan
    Tran, Dollnovan
    Sprehe, Leslie
    Weiler, Andrea
    Mostrom, Matilda
    Fitzpatrick-Schmidt, Taylor
    Friedrich, Thomas
    Schaub, Robert
    Braun, Stephen E.
    Kaur, Amitinder
    [J]. JOURNAL OF MEDICAL PRIMATOLOGY, 2020, 49 (05) : 267 - 268
12345